Zimbabwe has declined a significant US health deal worth $367m (£272m) spanning five years over the United States' request for sensitive biological samples.
The decision became public following a official document dated December was disclosed, which showed Head of State Emmerson Mnangagwa felt the deal was "skewed".
A government representative later stated that the United States was demanding access to biological samples for scientific study and commercial gain but was not willing to share the resulting advantages from future vaccines.
"We must now begin the challenging and unfortunate task of ending our support in Zimbabwe," stated American envoy to Zimbabwe Pamela Tremont publicly.
Her embassy indicated the United States had provided more than $1.9bn in health funding to Zimbabwe over the last twenty years.
A doctors' association in Zimbabwe has appealed for further dialogue to secure a deal acceptable to all parties so the country's vital HIV treatment initiative can proceed.
Broader Context
Zimbabwe's decision comes after a comparable situation in Kenya, where a court halted a related health funding agreement following concerns were raised about the safety of citizens' health data.
Since resuming the presidency recently, US President Donald Trump has drastically cut foreign aid and closed the key foreign aid agency.
USAID had overseen assistance for the US government, but Trump argued its expenditure was "inefficient" and his government was seeking government-to-government agreements to enhance transparency and accountability.
As per reports, 16 African countries have so far agreed to these new agreements, constituting over $18.3bn in committed funds.
Specifics of the Rejected Deal
The money for Zimbabwe was intended to gone towards "tackling HIV/Aids, TB, malaria, healthcare for mothers and children, and disease outbreak preparedness.
"We are confident this partnership might have yielded extraordinary benefits for Zimbabwean communities, especially the 1.2 million men, women and children presently receiving antiretroviral therapy through US-supported programmes," Tremont said.
However, government spokesperson Nick Mangwana argued the arrangement was "asymmetrical".
"Our nation was requested to share its biological resources and data for a long time, with no equivalent assurance of access to any scientific breakthroughs – such as vaccines, diagnostics, or treatments – that might be developed from that shared data," his statement read.
"Put simply, our nation would provide the raw materials for medical research with no certainty that the end products would be accessible to our citizens should a future health crisis emerge."
National Interest and International Frameworks
Mangwana further noted that the American exit from the global health body and its pursuit of bilateral health agreements were undermining systems already established via the international organization.
The spokesperson gave as an example its Pandemic Benefit-Sharing system created to manage future global health emergencies.
"This system is designed to guarantee that when a nation provides its samples, the benefits – such as vaccines and treatments – are distributed fairly, not monopolised exclusively by those with the capability to create them."
Zimbabwe's reservations regarding the US deal "should not be misconstrued as anti-American sentiment," Mangwana stressed.
"We welcome further discussions with our American counterparts on how subsequent co-operation could be arranged in a manner that respects the independence and dignity of both nations."
Health Experts Reaction
Medical experts said it recognised the government's concerns, but recommended that talks need to persist considering a large portion of the country's HIV programmes depended on international support.
"If technical issues exist, such as those involving information security or implementation frameworks, these can frequently be resolved through detailed discussion and negotiated safeguards," the group added.
The situation underscores the continuing challenges between accepting vital foreign assistance and safeguarding a country's data in an ever more interconnected world.